<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088216</url>
  </required_header>
  <id_info>
    <org_study_id>NCFB-FLS-01</org_study_id>
    <nct_id>NCT02088216</nct_id>
  </id_info>
  <brief_title>Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis</brief_title>
  <acronym>BENE</acronym>
  <official_title>Effect of N-acetylcysteine on Exacerbations of Bronchiectasis (BENE): a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <brief_summary>
    <textblock>
      Objective: To evaluate whether long-term oral N-acetylcysteine as an expectorant drug can
      reduce the frequency of acute exacerbations of patients with non-cystic fibrosis
      bronchiectasis and improve their quality of life.

      Methods: Patients with non-cystic fibrosis bronchiectasis will be randomly assigned to the
      observer group (participants receive 600 mg of oral N-acetylcysteine BID for 12 months) or
      the control group (participants receive oral tablet BID for 12 months). The primary endpoint
      was the frequency of acute exacerbations.

      Expected results: Compared with the control group, the frequency of acute exacerbations of
      the observer Group will decrease significantly.

      Hypothesis: Long-term oral N-acetylcysteine can reduce the frequency of acute exacerbations
      of patients with non-cystic fibrosis bronchiectasis and improve their quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: N-acetylcysteine is a classic mucolytic agent. This study aimed to investigate the
      efficacy and safety of N-acetylcysteine on the risk of exacerbations in bronchiectasis
      patients.

      Methods: A prospective, randomized, controlled trial was conducted between April 1, 2014 and
      December 31, 2016 in five general hospitals in Shandong Province, China. Adult bronchiectasis
      patients with at last two exacerbations in the past year were potentially eligible. Patients
      were randomly assigned to receive oral N-acetylcysteine (600 mg, twice daily, 12 months) or
      on-demand treatment.

      Results: A total of 161 patients were eligible for randomization (81 to the N-acetylcysteine
      group and 80 to the control group). During the 12-month follow-up, the incidence of
      exacerbations in the N-acetylcysteine group was significantly lower than that in the control
      group (1.31 vs. 1.98 exacerbations per patient-year; risk ratio, 0.41; 95% CI, 0.17-0.66; P =
      0.0011). The median number of exacerbations in the N-acetylcysteine group was 1 (0.5-2),
      compared with 2 (1-2) in the control group (U=-2.95, P = 0.003). No severe adverse events
      were reported in the intervention group.

      Conclusion: The long-term use of N-acetylcysteine is able to reduce the risk of exacerbations
      for bronchiectasis patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Actual">March 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Number of Exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>An exacerbation of bronchiectasis is defined as either a change in one or more of the common symptoms of bronchiectasis (sputum volume or purulence, dyspnea, cough, and fatigue/malaise) or the onset of new symptoms (fever, pleurisy, haemoptysis or need for antibiotic treatment).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Volume of Sputum From Baseline Parameters After the 12-month Follow-up.</measure>
    <time_frame>12 months</time_frame>
    <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa</measure>
    <time_frame>12 months</time_frame>
    <description>The values in the table were calculated as the value at baseline minus the value at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores From Baselines</measure>
    <time_frame>12 months</time_frame>
    <description>Chronic Obstructive Pulmonary Disease Assessment Test (CAT) scores: the minimum value is 0 and the maximum value is 40.
0-10 points: &quot;slight impact&quot;; 11-20 points: &quot;medium impact&quot;; 21-30 points: &quot;serious impact&quot;; 31-40 points: &quot;very serious impact&quot;.
The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percentage of Predicted Forced Expiratory Volume in One Second (FEV1%) From Baselines</measure>
    <time_frame>12 months</time_frame>
    <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Forced Expiratory Volume in One Second (FEV1) (L) From Baselines</measure>
    <time_frame>12 months</time_frame>
    <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Forced Vital Capacity (FVC) From Baselines</measure>
    <time_frame>12 months</time_frame>
    <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Exacerbation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Recurrent Exacerbations</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature of Sputum (Number of Patients With Yellow Purulent)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) (Elevation of Liver Enzymes)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Non-Cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>N-Acetylcysteine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 600 mg of oral N-acetylcysteine BID for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants received as-needed therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>600mg po twice a day for 12 months</description>
    <arm_group_label>N-Acetylcysteine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>On-demand treatment</intervention_name>
    <description>receive as-needed therapy</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. subjects were aged 18-80 years old;

          2. a diagnosis of idiopathic or post-infective bronchiectasis was made;

          3. patients had at least two exacerbations in the past year and were in a stable state
             for at least 4 weeks prior to the primary enrollment.

        Exclusion Criteria:

        Patients were excluded if they fulfilled any of the following criteria: current smokers;
        cigarette smoking within 6 months; cystic fibrosis or other etiologies (such as
        immunodeficiency, allergic bronchopulmonary aspergillosis, traction bronchiectasis caused
        by emphysema, advanced pulmonary fibrosis, etc.); pulmonary function test results showing a
        forced expiratory volume in 1 s (FEV1) â‰¤ 30% of the predicted value; a history of severe
        cardiovascular or neurological disease; comorbidity with liver disease, kidney disease,
        malignant tumor, gastric ulcer, or intestinal malabsorption; a known allergy to
        N-acetylcysteine; pregnancy or lactation (for women); a history of prior macrolide use of
        more than 1 week; and poor compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Li, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <results_first_submitted>August 17, 2018</results_first_submitted>
  <results_first_submitted_qc>February 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2019</results_first_posted>
  <last_update_submitted>February 16, 2019</last_update_submitted>
  <last_update_submitted_qc>February 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Qian Qi</investigator_full_name>
    <investigator_title>assistant director</investigator_title>
  </responsible_party>
  <keyword>N-acetylcysteineï¼›</keyword>
  <keyword>Bronchiectasisï¼›</keyword>
  <keyword>Acute exacerbationsï¼›</keyword>
  <keyword>Antioxidantï¼›</keyword>
  <keyword>Anti-inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02088216/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02088216/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine Group</title>
          <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Participants received on-demand treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine Group</title>
          <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Participants received on-demand treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="161"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.28" spread="11.90"/>
                    <measurement group_id="B2" value="56.56" spread="12.41"/>
                    <measurement group_id="B3" value="54.91" spread="12.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="81"/>
                    <count group_id="B2" value="80"/>
                    <count group_id="B3" value="161"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Number of Exacerbations</title>
        <description>An exacerbation of bronchiectasis is defined as either a change in one or more of the common symptoms of bronchiectasis (sputum volume or purulence, dyspnea, cough, and fatigue/malaise) or the onset of new symptoms (fever, pleurisy, haemoptysis or need for antibiotic treatment).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Exacerbations</title>
          <description>An exacerbation of bronchiectasis is defined as either a change in one or more of the common symptoms of bronchiectasis (sputum volume or purulence, dyspnea, cough, and fatigue/malaise) or the onset of new symptoms (fever, pleurisy, haemoptysis or need for antibiotic treatment).</description>
          <units>exacerbations</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.5" upper_limit="2"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Volume of Sputum From Baseline Parameters After the 12-month Follow-up.</title>
        <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Volume of Sputum From Baseline Parameters After the 12-month Follow-up.</title>
          <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.46" spread="22.93"/>
                    <measurement group_id="O2" value="-18.28" spread="25.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa</title>
        <description>The values in the table were calculated as the value at baseline minus the value at 12 months.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Number of Patients With a Positive Sputum Culture for Pseudomonas Aeruginosa</title>
          <description>The values in the table were calculated as the value at baseline minus the value at 12 months.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores From Baselines</title>
        <description>Chronic Obstructive Pulmonary Disease Assessment Test (CAT) scores: the minimum value is 0 and the maximum value is 40.
0-10 points: &quot;slight impact&quot;; 11-20 points: &quot;medium impact&quot;; 21-30 points: &quot;serious impact&quot;; 31-40 points: &quot;very serious impact&quot;.
The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) Scores From Baselines</title>
          <description>Chronic Obstructive Pulmonary Disease Assessment Test (CAT) scores: the minimum value is 0 and the maximum value is 40.
0-10 points: &quot;slight impact&quot;; 11-20 points: &quot;medium impact&quot;; 21-30 points: &quot;serious impact&quot;; 31-40 points: &quot;very serious impact&quot;.
The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.79" spread="5.40"/>
                    <measurement group_id="O2" value="-1.44" spread="6.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percentage of Predicted Forced Expiratory Volume in One Second (FEV1%) From Baselines</title>
        <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percentage of Predicted Forced Expiratory Volume in One Second (FEV1%) From Baselines</title>
          <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
          <units>percentage of predicted FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="16.50"/>
                    <measurement group_id="O2" value="0.13" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Forced Expiratory Volume in One Second (FEV1) (L) From Baselines</title>
        <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Forced Expiratory Volume in One Second (FEV1) (L) From Baselines</title>
          <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.37"/>
                    <measurement group_id="O2" value="0.03" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Forced Vital Capacity (FVC) From Baselines</title>
        <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Forced Vital Capacity (FVC) From Baselines</title>
          <description>The change was calculated from two time points as the value at the later time point minus the value at the earlier time point.</description>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.46"/>
                    <measurement group_id="O2" value="0.03" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Exacerbation</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Exacerbation</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140" lower_limit="95.90" upper_limit="184.10"/>
                    <measurement group_id="O2" value="115" lower_limit="77.75" upper_limit="152.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Recurrent Exacerbations</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Recurrent Exacerbations</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.70" lower_limit="297.05" upper_limit="330.36"/>
                    <measurement group_id="O2" value="266.88" lower_limit="244.60" upper_limit="289.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nature of Sputum (Number of Patients With Yellow Purulent)</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Nature of Sputum (Number of Patients With Yellow Purulent)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AEs) (Elevation of Liver Enzymes)</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine Group</title>
            <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Participants received on-demand treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AEs) (Elevation of Liver Enzymes)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine Group</title>
          <description>Participants received oral N-acetylcysteine (600 mg, twice daily, 12 months).</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Participants received on-demand treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="81"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yu Li</name_or_title>
      <organization>Qilu Hospital of Shandong University</organization>
      <phone>13791122770</phone>
      <email>qlliyu@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

